MedTrace Logo

Combination of Ibrutinib and As2O3 in the Treatment of CLL

NCT02757040 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2016-04-29

No results posted yet for this study

Summary

The purpose of this study is to determine whether the combination of As2O3 and ibrutinib is synergistic in chronic lymphocytic leukemia

Conditions

  • Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

DRUG

Ibrutinib combined with As2O3

arsenic trioxide combined with ibrutinib in CLL

DRUG

ibrutinib

ibrutinib

Sponsors & Collaborators

  • Beijing Hospital

    collaborator OTHER_GOV

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Xiao-Jun Huang, Doctor · Peking University People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2017-12-31
Completion
2018-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02757040 on ClinicalTrials.gov